Skip to main content

Table 5 Adverse events and hematologic abnormalities

From: Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort

  SOF + PEG + RBV SOF + RBV p value
total: 68 % (81) total: 32 % (38)
Adverse events   
 Headache 5 % (4) 5 % (2) 0.9515
 Fatigue 18 % (14) 16 % (6) 0.8170
 Myalgia 15 % (12) 11 % (4) 0.5072
 Hashimoto’s thyroiditis 5 % (4) 0 0.1608
 Decreased appetite 3 % (2) 0 0.3256
 Rash 5 % (4) 0 0.1608
 Thrush 1 % (1) 0 0.4888
 Hair loss 10 % (8) 0 0.0435
 Aggressiveness 6 % (5) 0 0.1153
 Pruritus 5 % (4) 0 0.1608
 Insomnia 3 % (2) 3 % (1) 0.9662
 Depression 3 % (2) 0 0.3256
 Acute psychosis 1 % (1) 0 0.4888
Hematologic abnormalities    
 Anemia (<10 g dl-1) 75 % (60) 37 % (14) <0.0001
 Leukocytopenia (<3 10E3 μl-1) 75 % (60) 16 % (6) <0.0001
 Thrombocytopenia (<100 10E3 μl-1) 60 % (48) 5 % (2) <0.0001
  1. Data are expressed as percent (number)
  2. SOF sofosbuvir, PEG pegylated-interferon, RBV ribavirin
  3. Boldface data statistically significant